Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.

Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31

High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol (1999) 2.08

A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J Virol (2002) 2.02

Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J Clin Microbiol (2001) 1.79

The role of therapeutic drug monitoring in treatment of HIV infection. Br J Clin Pharmacol (2001) 1.14

A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis (2011) 1.07

Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir. J Virol (2005) 0.97

Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations. J Virol (2005) 0.96

Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS (2008) 0.91

Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring. J Epidemiol Community Health (2006) 0.86

A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300. Clin Diagn Lab Immunol (2000) 0.85

Clinical, immunological and virological evolution in patients with CD4 T-cell count above 500/mm3: is there a benefit to treat with highly active antiretroviral therapy (HAART)? Eur J Epidemiol (2004) 0.82

Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers. Br J Clin Pharmacol (2003) 0.81

Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors. Curr Infect Dis Rep (2001) 0.80

Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (2001) 0.77

Translational HIV-1 research: from routine diagnostics to new virology insights in Amsterdam, the Netherlands during 1983-2013. Retrovirology (2013) 0.76

When to Start Antiretroviral Therapy and What to Start With-- A European Perspective. Curr Infect Dis Rep (2003) 0.76

Virologic and Immunologic Response to Highly Active Antiretroviral Therapy. Curr Infect Dis Rep (2002) 0.75

Immunological profile in persons under antiretroviral therapy in a rural Nigerian hospital. J Public Health Africa (2010) 0.75

Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol (1992) 10.25

Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32

Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94

Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science (1999) 7.66

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA (1998) 7.00

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet (2004) 6.27

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science (1997) 5.55

Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis (1995) 4.60

Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet (1986) 4.54

Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol (1991) 4.48

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis (1992) 4.21

Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet (1989) 4.19

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med (2001) 3.74

Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med (2000) 3.70

Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61

Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest (1988) 3.59

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet (1999) 3.41

Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) (1986) 3.27

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 3.23

Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis (1992) 3.16

A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J Virol Methods (1994) 3.13

Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med (1997) 3.08

Clinical significance of small-intestinal microsporidiosis in HIV-1-infected individuals. Lancet (1991) 2.87

Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. Br Med J (Clin Res Ed) (1986) 2.75

Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet (1998) 2.67

Diagnosis of intestinal and disseminated microsporidial infections in patients with HIV by a new rapid fluorescence technique. J Clin Pathol (1993) 2.52

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet (1990) 2.50

Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS (2001) 2.41

Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A (1998) 2.39

The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med (2006) 2.38

Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet (1988) 2.38

Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS (1992) 2.35

Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol (1987) 2.32

A Bayesian approach to parameter estimation in HIV dynamical models. Stat Med (2002) 2.30

Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis (2004) 2.26

Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS (1998) 2.19

Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection. J Infect Dis (1987) 2.17

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS (2000) 2.14

Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. AIDS (1998) 2.14

T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover. Science (1996) 2.12

Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS (1999) 2.09

Impact of HIV antibody testing on changes in sexual behavior among homosexual men in The Netherlands. Am J Public Health (1988) 2.07

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol (1997) 2.07

Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis (1988) 2.06

Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis (1990) 2.06

The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS (1992) 2.06

Risk factors for human herpesvirus 8 seropositivity and seroconversion in a cohort of homosexual men. Am J Epidemiol (2000) 2.05

Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci (2001) 2.04

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03

Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. Br Med J (Clin Res Ed) (1987) 2.02

[Therapeutic options for HIV infection should lead to increased utilization of HIV tests]. Ned Tijdschr Geneeskd (1999) 2.01

High viral burden in the presence of major HIV-specific CD8(+) T cell expansions: evidence for impaired CTL effector function. Eur J Immunol (2001) 1.99

HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Lancet (1997) 1.98

Cardio- and cerebrovascular events in HIV-infected persons. AIDS (2004) 1.98

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet (1999) 1.95

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis (2013) 1.91

Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet (1998) 1.88

Pulmonary tuberculosis due to Mycobacterium microti in a human immunodeficiency virus-infected patient. Clin Infect Dis (1998) 1.87

The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology (1994) 1.85

Ongoing HIV dissemination during HAART. Nat Med (1999) 1.85

Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS (1993) 1.85

Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual. J Virol (1991) 1.83

Curcumin is an in vivo inhibitor of angiogenesis. Mol Med (1998) 1.81

Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 1.81

Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS (2001) 1.81